{"id":"https://openalex.org/W2763707017","doi":null,"title":"Triple-Bead Mixed Amphetamine Salt for ADHD","display_name":"Triple-Bead Mixed Amphetamine Salt for ADHD","publication_year":2017,"publication_date":"2017-08-01","ids":{"openalex":"https://openalex.org/W2763707017","mag":"2763707017"},"language":"en","primary_location":{"id":"mag:2763707017","doi":null,"is_oa":false,"landing_page_url":"https://www.questia.com/library/journal/1G1-502507738/triple-bead-mixed-amphetamine-salt-for-adhd","pdf_url":null,"source":{"id":"https://openalex.org/S2764520953","display_name":"Current psychiatry","issn_l":"1537-8276","issn":["1537-8276"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","poland-20","russia-white-list-4"],"host_organization":"https://openalex.org/P4322696809","host_organization_name":"Frontline Medical Communications","host_organization_lineage":["https://openalex.org/P4322696809"],"host_organization_lineage_names":["Frontline Medical Communications"],"type":"journal"},"license":null,"license_id":null,"version":null,"is_accepted":false,"is_published":false,"raw_source_name":"Current psychiatry","raw_type":null},"volume":null,"type":"article","is_traditional":true,"indexed_in":[],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5010194987","display_name":"Jeffrey Robert Strawn","orcid":"https://orcid.org/0000-0002-7526-2641","observed_orcids":["https://orcid.org/0000-0002-7526-2641"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Jeffrey R. Strawn","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0002-7526-2641","affiliations":[]},{"author_position":"last","author":{"id":"https://openalex.org/A5024009838","display_name":"Lara S. Picard","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Lara S. Picard","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]}],"institutions":[],"countries_distinct_count":0,"institutions_distinct_count":0,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":0.0,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":{"value":0.19257062,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":null,"biblio":{"volume":"16","issue":"8","first_page":"33","last_page":null},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10537","display_name":"Attention Deficit Hyperactivity Disorder","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2738","display_name":"Psychiatry and Mental health"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10537","display_name":"Attention Deficit Hyperactivity Disorder","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2738","display_name":"Psychiatry and Mental health"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T12547","display_name":"Pharmaceutical studies and practices","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2735","display_name":"Pediatrics, Perinatology and Child Health"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T12539","display_name":"Pharmacology and Obesity Treatment","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2736","display_name":"Pharmacology (medical)"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/attention-deficit-hyperactivity-disorder","display_name":"attention deficit hyperactivity disorder","score":0.6399999856948853},{"id":"https://openalex.org/keywords/long-acting-stimulants","display_name":"long-acting stimulants","score":0.8199999928474426},{"id":"https://openalex.org/keywords/extended-release-formulation","display_name":"sustained-release formulation","score":0.6230000257492065},{"id":"https://openalex.org/keywords/pharmacokinetics","display_name":"pharmacokinetics","score":0.746999979019165},{"id":"https://openalex.org/keywords/monoamine-oxidase-inhibition","display_name":"monoamine oxidase inhibition","score":0.968999981880188},{"id":"https://openalex.org/keywords/once-daily-dosing","display_name":"once-daily dosing","score":0.6439999938011169},{"id":"https://openalex.org/keywords/adolescents-and-adults","display_name":"adolescents and adults","score":0.5540000200271606},{"id":"https://openalex.org/keywords/adverse-effects","display_name":"adverse effects","score":0.382999986410141},{"id":"https://openalex.org/keywords/fda-approval","display_name":"FDA approval","score":0.40400001406669617},{"id":"https://openalex.org/keywords/adhd-medication","display_name":"ADHD medication","score":0.4869999885559082},{"id":"https://openalex.org/keywords/prefrontal-cortex","display_name":"prefrontal cortex","score":0.46000000834465027}],"concepts":[{"id":"https://openalex.org/C2778375690","wikidata":"https://www.wikidata.org/wiki/Q7814214","display_name":"Tolerability","level":3,"score":0.710321843624115},{"id":"https://openalex.org/C2780557958","wikidata":"https://www.wikidata.org/wiki/Q211036","display_name":"Stimulant","level":2,"score":0.6690236330032349},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.6211821436882019},{"id":"https://openalex.org/C2777193897","wikidata":"https://www.wikidata.org/wiki/Q179452","display_name":"Amphetamine","level":3,"score":0.5895675420761108},{"id":"https://openalex.org/C46821324","wikidata":"https://www.wikidata.org/wiki/Q7094540","display_name":"Onset of action","level":2,"score":0.5295798778533936},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.4920622706413269},{"id":"https://openalex.org/C2777112843","wikidata":"https://www.wikidata.org/wiki/Q422112","display_name":"Methylphenidate","level":3,"score":0.4658896028995514},{"id":"https://openalex.org/C3019981671","wikidata":"https://www.wikidata.org/wiki/Q5165929","display_name":"Immediate release","level":2,"score":0.4517100751399994},{"id":"https://openalex.org/C2780783007","wikidata":"https://www.wikidata.org/wiki/Q181923","display_name":"Attention deficit hyperactivity disorder","level":2,"score":0.38124632835388184},{"id":"https://openalex.org/C118552586","wikidata":"https://www.wikidata.org/wiki/Q7867","display_name":"Psychiatry","level":1,"score":0.25827649235725403},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.1820148229598999},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.1144249439239502},{"id":"https://openalex.org/C513476851","wikidata":"https://www.wikidata.org/wiki/Q170304","display_name":"Dopamine","level":2,"score":0.07545113563537598}],"mesh":[],"locations_count":1,"locations":[{"id":"mag:2763707017","doi":null,"is_oa":false,"landing_page_url":"https://www.questia.com/library/journal/1G1-502507738/triple-bead-mixed-amphetamine-salt-for-adhd","pdf_url":null,"source":{"id":"https://openalex.org/S2764520953","display_name":"Current psychiatry","issn_l":"1537-8276","issn":["1537-8276"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","poland-20","russia-white-list-4"],"host_organization":"https://openalex.org/P4322696809","host_organization_name":"Frontline Medical Communications","host_organization_lineage":["https://openalex.org/P4322696809"],"host_organization_lineage_names":["Frontline Medical Communications"],"type":"journal"},"license":null,"license_id":null,"version":null,"is_accepted":false,"is_published":false,"raw_source_name":"Current psychiatry","raw_type":null}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being","score":0.9537000060081482}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2076504554","https://openalex.org/W2058463020","https://openalex.org/W2743807096","https://openalex.org/W2127950942","https://openalex.org/W4390791628","https://openalex.org/W2605555742","https://openalex.org/W2740252718","https://openalex.org/W2605977622","https://openalex.org/W2070994413","https://openalex.org/W2159184227"],"abstract_inverted_index":{"Stimulants":[0],"are":[1,82,413,443,468,538],"first-line":[2],"psychopharmacologic":[3],"interventions":[4],"for":[5,125,357,389,396,456],"attention-deficit/hyperactivity":[6],"disorder":[7],"(ADHD),":[8],"and":[9,17,21,33,61,139,201,233,267,307,323,330,351,359,371,391,398,405,410,422,486,544,552,558,565],"their":[10,37,46],"efficacy":[11,34],"is":[12,44,54,384,523,528,555],"supported":[13],"by":[14,378],"clinical":[15],"trials":[16],"meta-analyses":[18],"in":[19,131,310,328,424,438,475,561],"children":[20],"adolescents":[22,132,339],"(1)":[23],"as":[24,26,505,507],"well":[25,506],"adults.":[27],"(2)":[28],"Despite":[29],"decades":[30],"of":[31,42,99,129,154,169,171,184,186,199,207,255,265,272,283,291,346,493,532,550],"tolerability":[32],"data":[35],"supporting":[36],"use,":[38],"a":[39,77,90,146,161,229,245,343,524,529],"major":[40],"drawback":[41],"stimulants":[43,188],"that":[45,95,166,190,483,497],"salutary":[47],"therapeutic":[48],"effects":[49],"wane":[50],"once":[51],"the":[52,85,97,121,126,167,172,179,263,281,300,354,447,547],"medication":[53,428],"cleared":[55],"or":[56,74,106,136,380,462,569],"metabolized.":[57],"Both":[58],"mixed":[59,114],"amphetamine-":[60],"methylphenidate-based":[62],"preparations":[63,81,537],"have":[64],"short":[65],"half-lives,":[66],"necessitating":[67],"multiple":[68],"doses":[69],"per":[70],"day":[71],"(eg,":[72,501,511],"3":[73,221],"4":[75,212],"times":[76],"day)":[78],"when":[79,535],"short-acting":[80],"used.":[83],"Over":[84],"past":[86],"15":[87],"years,":[88],"nearly":[89],"dozen":[91],"formulations":[92],"were":[93,341,361],"developed":[94],"extend":[96,151],"duration":[98,153,168,183],"action":[100,170,185,208,256],"through":[101,416],"delayed":[102,104],"release,":[103],"absorption,":[105],"utilizing":[107],"prodrugs.":[108],"In":[109,338],"June":[110],"2017,":[111],"long-acting,":[112,347],"triple-bead":[113,148,348],"amphetamine":[115,226,277,518,522],"salt":[116,227],"(MAS)":[117],"was":[118,159,164],"FDA-approved":[119],"under":[120,353],"brand":[122],"name":[123],"Mydayis":[124],"once-daily":[127],"treatment":[128],"ADHD":[130,564],"(age":[133],"[greater":[134],"than":[135],"equal":[137],"to]13)":[138],"adults":[140,369],"(Table":[141],"l).3":[142],"This":[143,192],"formulation":[144,195,261],"utilizes":[145],"unique":[147,246],"technology":[149,158],"to":[150,181,211,244,320,364,375,386,393],"its":[152],"action.":[155],"When":[156],"this":[157,260],"developed-nearly":[160],"decade":[162],"ago--it":[163],"hoped":[165],"stimulant":[173],"would":[174],"be":[175,376,431,473],"significantly":[176],"increased,":[177,432],"beyond":[178],"10-":[180],"12-hour":[182],"available":[187],"at":[189],"time.":[191],"newly":[193],"approved":[194],"provides":[196],"16":[197],"hours":[198,213,322,325,388,395],"coverage,":[200],"patients":[202,311,457,476,562],"may":[203,279,430,436,489],"experience":[204],"an":[205,224,234],"onset":[206],"within":[209,299],"2":[210],"following":[214,326],"administration.":[215],"(3)":[216,253,370,382,408,520],"The":[217],"encapsulated":[218],"preparation":[219],"contains":[220],"MAS":[222,551],"beads:":[223],"immediate-release":[225],"bead,":[228,232],"pulsed-delayed":[230],"release":[231],"extended-release":[235],"bead":[236],"(Figure":[237,249,334],"1,":[238],"page":[239,251,336],"34),":[240],"which":[241],"give":[242],"rise":[243],"pharmacokinetic":[247],"profile":[248],"2,":[250,335],"35).":[252],"Mechanism":[254],"Like":[257],"all":[258],"MAS,":[259,349],"blocks":[262],"reuptake":[264],"norepinephrine":[266],"dopamine,":[268],"increasing":[269,288],"synaptic":[270,289],"concentrations":[271,492],"these":[273],"monoamine":[274,284],"neurotransmitters.":[275],"Additionally,":[276],"salts":[278],"inhibit":[280],"activity":[282,463],"oxidase":[285],"(MAO),":[286],"further":[287],"levels":[290],"monoamines.":[292],"(4)":[293,314],"Enhancing":[294],"noradrenergic,":[295],"dopaminergic":[296],"neurotransmission,":[297],"particularly":[298],"prefrontal":[301],"cortex,":[302],"increases":[303],"attention,":[304],"working":[305],"memory,":[306],"processing":[308],"speed":[309],"with":[312,368,477,541,563],"ADHD.":[313],"Pharmacokinetics":[315],"Cmax":[316,350],"occurs":[317],"approximately":[318],"7":[319],"10":[321,385,392],"8":[324],"administration":[327],"adolescent":[329],"adult":[331,406],"patients,":[332],"respectively":[333],"35)?":[337],"who":[340],"administered":[342],"single":[344],"dose":[345],"area":[352],"curve":[355],"(AUC)":[356],"d-":[358],"l-amphetamine":[360],"both":[362],"21%":[363],"31%":[365],"higher":[366],"compared":[367],"did":[372],"not":[373,400],"appear":[374],"affected":[377],"sex":[379],"race.":[381],"Half-life":[383],"11":[387],"d-amphetamine":[390],"13":[394],"1-amphetamine":[397],"does":[399],"statistically":[401],"differ":[402],"between":[403],"pediatric":[404],"studies.":[407],"Metabolism":[409],"elimination.":[411],"Amphetamines":[412],"partially":[414],"metabolized":[415],"cytochrome":[417],"450":[418],"(CYP)":[419],"2D6-dependent":[420],"mechanisms,":[421],"thus":[423],"CYP2D6":[425,460],"poor":[426],"metabolizers":[427],"exposure":[429,435],"while":[433],"decreased":[434],"occur":[437],"ultra-rapid":[439],"metabolizers;":[440],"however,":[441],"there":[442,527],"no":[444],"guidelines":[445],"from":[446],"Clinical":[448],"Pharmacogenetics":[449],"Implementation":[450],"Consortium":[451],"regarding":[452],"alternate":[453],"dosing":[454],"strategies":[455],"based":[458],"on":[459],"genotype":[461],"phenotype.":[464],"(5)":[465],"Because":[466,521],"amphetamines":[467],"renally":[469],"excreted,":[470],"dosages":[471],"should":[472],"adjusted":[474],"renal":[478],"impairment.":[479],"Drug":[480],"interactions.":[481],"Medications":[482],"affect":[484,490],"gastrointestinal":[485],"urinary":[487,508],"pH":[488,500],"serum":[491,517],"amphetamine.":[494],"Specifically,":[495],"agents":[496,510],"increase":[498,516],"gastric":[499],"proton":[502],"pump":[503],"inhibitors)":[504],"alkalinizing":[509],"acetazolamide,":[512],"some":[513],"thiazide":[514],"diuretics)":[515],"concentrations.":[519],"weak":[525],"MAOI,":[526],"theoretical":[530],"risk":[531],"serotonin":[533],"syndrome":[534],"amphetamine-based":[536],"used":[539],"concurrently":[540],"SSRIs,":[542],"TCAs,":[543],"MAOIs.":[545],"However,":[546],"concurrent":[548],"use":[549],"SSRIs":[553],"generally":[554],"considered":[556],"safe":[557],"common":[559],"practice":[560],"co-occurring":[566],"anxiety":[567],"(6,7)":[568],"depressive":[570],"disorders.":[571],"\u2026":[572]},"counts_by_year":[],"updated_date":"2026-11-04T10:54:05.112534","created_date":"2017-10-20T00:00:00"}